Q-omics provides the consensus-scored FAM122C profile across patient tissues and cancer cell-line models. FAM122C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FAM122C is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, FAM122C RNA expression shows 20,995 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, HNSC, and ACC as cancer lineages where FAM122C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM122C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM122C survival associations across molecular data types. FAM122C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM122C RNA expression–survival associations across cancer types. High FAM122C expression shows unfavorable associations in LGG, ACC and UVM, but favorable associations in LUAD, SKCM and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for FAM122C RNA expression.
This table summarizes FAM122C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM122C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM122C shows lower tumor expression in LUSC and KICH and higher tumor expression in HNSC, CHOL, COAD and LIHC. The HNSC box plot shows higher FAM122C RNA expression in tumor versus normal tissue (log2 FC = +0.349, t-test p < 0.001).
This table shows molecular features associated with FAM122C in patient tissues and cancer cell lines. In patient samples, FAM122C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM122C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
